Table 1 Patient Demographics
Characteristic | “B in IT” patients | Control patients | P values |
|---|---|---|---|
Total Number | 30 | 60 | |
Female | 19 (63.3%) | 38 (63.3%) | 1.000 |
Male | 11 (36.7%) | 22 (36.7%) | 1.000 |
Age (years) mean ± SD | 55.6 ± 12.6 | 55.3 ± 11.6 | 0.985 |
Female | 53.8 ± 10.7 | 54.0 ± 10.4 | 0.867 |
Male | 58.6 ± 15.4 | 57.6 ± 13.4 | 0.889 |
Ethnicity | |||
Asian | 24 (80%) | 48 (80%) | 1.000 |
Sub-Saharan African | 3 (10%) | 6 (10%) | 1.000 |
European | 2 (6.7%) | 4 (6.7%) | 1.000 |
Pacific Islander | 1 (3.3%) | 2 (3.3%) | 1.000 |
Preferred Language | |||
English | 12 (40%) | 30 (50%) | 0.502 |
Vietnamese | 6 (20%) | 14 (23.3%) | 0.794 |
Mandarin | 4 (13.3%) | 7 (11.7%) | 1.000 |
Hakka Timorese | 3 (10%) | 1 (1.7%) | 0.106 |
Cantonese | 2 (6.7%) | 4 (6.7%) | 1.000 |
Other | 3 (10%) | 4 (6.7%) | 0.682 |
Liver Clinic Visits | |||
< 5 | 10 (33.3%) | 11 (18.3%) | 0.185 |
5-10 | 8 (26.7%) | 13 (21.7%) | 0.791 |
> 10 | 12 (40%) | 36 (60%) | 0.116 |
Breaks in care (> 1 year) | |||
N/A (seen < 1 year) | 9 (30%) | 4 (6.7%) | 0.005a |
0 | 12 (40%) | 47 (78.3%) | 0.0005a |
1 | 7 (23.3%) | 6 (10%) | 0.115 |
2 | 1 (3.3%) | 3 (5%) | 1.000 |
> 2 | 1 (3.3%) | 0 (0%) | 0.333 |
HBeAg Status | |||
Negative | 29 (96.7%) | 57 (95%) | 1.000 |
Positive | 1 (3.3%) | 3 (5%) | 1.000 |
Phase of disease | |||
1 – immune tolerance | 0 (0%) | 0 (0%) | 1.000 |
2 – immune clearance | 1 (3.3%) | 3 (5%) | 1.000 |
3 – immune control | 23 (76.7%) | 44 (73.3%) | 0.802 |
4 – immune escape | 5 (16.7%) | 9 (15%) | 1.000 |
Cleared (HBsAb positive) | 1 (3.3%) | 4 (6.7%) | 0.661 |
Cirrhosis | 0 (0%) | 0 (0%) | 1.000 |
Treatment type | |||
Monitoring | 24 (80%) – 20 with HCC screening | 48 (80%) – 40 with HCC screening | 1.000 |
Antiviral therapy | 6 (20%) – 5 with HCC screening | 12 (20%) – 10 with HCC screening | 1.000 |
Entecavir | 5 (16.7%) | 10 (16.7%) | 1.000 |
Tenofovir | 1 (3.3%) | 2 (3.3%) | 1.000 |